.jpeg)
{{ variable.name }}
Enasidenib Instructions
Common name: Enasidenib
Trade name: Idhifa
All names: Ensidipine, Idhifa, Enasidenib
Usage and dosage:
100 mg orally once daily until disease progression or unacceptable toxicity.
Adverse reactions:
>10%:
Endocrine and metabolism: decreased serum calcium (74%), decreased serum potassium (41%)
Gastrointestinal tract: nausea (50%), diarrhea (43%), decreased appetite (34%), vomiting (3 4%), loss of appetite (12%)
Hematology and tumors: abnormal phosphorus levels (27%; grade ≥3: 8%; reduced), differentiation syndrome (14%), leukocytosis (12%; grade ≥3: 6%; non-infectious)
Liver: elevated serum bilirubin (81%)
1% -10%:
Hematology and tumors: tumor lysis syndrome (6%)
Respiratory system: acute respiratory distress (≤10%), pulmonary edema (≤10%)
Contraindications:
Pregnant or breastfeeding women should not take ensidipine (Idhifa/Enasidenib) as it may cause harm to the developing fetus or newborn baby.
Notes:
Embryo-fetal toxicity: Based on animal embryo-fetal toxicity studies, administration of IDHIFA® to pregnant women can cause embryo-fetal harm. Advise women of childbearing potential and men with female partners of childbearing potential to use an effective method of contraception during treatment with IDHIFA® and for at least 2 months after the last dose. Pregnant women who become pregnant while using IDHIFA® or male patients who have a pregnant female partner should be informed of the potential risks to the fetus.
Elevated bilirubin: IDHIFA® may interfere with bilirubin metabolism by inhibiting UGT1A1.
Non-infectious leukocytosis: IDHIFA® can induce bone marrow hyperplasia, leading to a rapid increase in white blood cell count
Tumor lysis syndrome: IDHIFA® can induce myeloid proliferation, leading to a rapid reduction of tumor cells, which may contribute to the risk of TLS.
1. Store Idhifa at room temperature between 68°F and 77°F (20°C and 25°C).
2. Store IDHIFA in its original container.
3. Keep the desiccant in the bottle and close the container tightly to prevent the tablets from absorbing moisture. u2003
Mechanism of action:
Ensidipine Idhifa (Enasidenib) is an isocitrate dehydrogenase 2 (IDH2) inhibitor. The tricarboxylic acid cycle (TCA cycle) is essential for many biochemical signaling pathways. IDH2 is a key enzyme in the tricarboxylic acid cycle. Certain mutant forms of this protein (R140Q, R172S, R172K) lead to an increase in the specific metabolite 2-hydroxyglutarate (2-HG). Ensidipine can reduce the content of 2-HG and induce leukemia cell differentiation.